又一创新药企上岸!下一步打造第二增长极

国际金融报
31 Mar

正值上市公司年报密集披露期,又一家创新药企宣布“上岸”,实现正向盈利。国内创新药企信达生物发布2024年年度业绩公告。财报信息显示,公司2024年全年收入达94.22亿元,同比增长51.8%。同时,得益于收入强劲增长、生产成本优化及营运效率的持续改善,公司于2024年实现非国际财务报告准则(Non-IFRS)计量下的利润及税息折旧及摊销前利润(EBITDA)转正。二级市场方面,财报发布后信达生物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10